Cellestia Biotech wins Sino-Swiss Business Awards

The Sino-Swiss Business Awards recognize companies that have made significant contribution to the Sino-Swiss business cooperation and the promotion of Switzerland in China. The jury also rewards entrepreneurs that have achieved distinct results and demonstrated the uppermost commitment to the Sino-Swiss community.

This year more than 80 Swiss and Chinese companies competed for awards in eight categories. During the award ceremony in China, over 400 guests including top political and business leaders from both Switzerland and China witnessed the awarding of the eight winners.

The startup Cellestia Biotech AG won the category ‘Swissnex Award for the Most Innovative Start-Up/ Entrepreneur’. The clinical-stage biotech company based in Basel is developing innovative first-in-class cancer drugs based on its innovative discovery platform. The company’s lead development candidate CB-103 targeted cancer therapy is a small molecule that inhibits the NOTCH signalling pathway –a key factor in certain cancers and in resistance to standard treatments. The company is conducting phase one clinical trials of its lead drug candidate in cancer patients in Europe, with planned expansion into China and the USA.

Acknowledging the achievements of Cellestia, the jury asserted that: “Due to its potential social and health benefit to cancer patients worldwide, Cellestia is a strong contender for this years’ Business Award for most innovative Start-Up/Entrepreneur.

(Press release/ran)